Clinical Trial Update: A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study of Repotrectinib in patients with advanced or metastatic solid tumors that harbor ALK, ROS1, or NTRK1-3 gene rearrangements; the trial is curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• Repotrectinib (repotrectinib)

Snippet

Sponsor: Turning Point Therapeutics, Inc. | Conditions: Locally Advanced Solid Tumors, Metastatic Solid Tumors | Phase 1, Phase 2 | Status: RECRUITING